Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To review the characteristics of children with non-classical 21-hydroxylase deficiency (NC-21-OHD) diagnosed during infancy and childhood, and to evaluate the relationship of pubertal and bone age maturation at initiation of glucocorticoid therapy with the course of puberty and final height. DESIGN: We retrospectively compared the course of puberty, growth pattern and final height in two groups of patients: group A (two males, six females), hydrocortisone (HC) treatment 7.5-15 mg/m2 per 24 h, initiated > or = 1 year before onset of true puberty and group B (seven females), treatment started with the first signs of true puberty present. PARTICIPANTS: Thirteen girls and two boys with NC-21-OHD diagnosed at age range 0.5-10.6 years were followed-up for 9.0 +/- 3.8 years (mean +/- S.D). Therapy with HC was initiated because of signs of hyperandrogenism, accelerated growth and bone maturation, or true precocious puberty. The HC dose was adjusted according to linear growth and basal plasma androgen levels. RESULTS: Puberty and peak height velocity developed significantly earlier in the girls of group B: gonadarche at 7.9 +/- 1.4 years and peak height velocity at 9.2 +/- 1.4 years vs 10.2 +/- 0.4 years (P = 0.002) and 11.5 +/- 0.7 years (P = 0.006) in group A. Menarche, however, occurred only slightly earlier in group B (12.0 +/- 1.1 vs 12.8 +/- 0.5 years, P = 0.068). All eight children in group A achieved a final height within the range of their mean parental height standard deviation scores (SDS) in comparison with only 1/7 in group B (P = 0.0014). Seven of eight patients who started therapy before a bone age of 9 years achieved a final height within the parental height SDS range, compared with 2/7 who started therapy later (P = 0.041). The final height SDS was significantly better for group A (0.05 +/- 0.19, mean +/- S.E.M.) than group B (-1.63 +/- 0.23, P = 0.0007), even when adjusted for a significant effect of the mean parental height SDS (A. -0.63 +/- 0.28; B, -0.89 +/- 0.31, P = 0.0245, ANCOVA). CONCLUSION: Every child with signs of excess androgen activity or early puberty should be studied for the possibility of NC-21-OHD. Screening programs for populations with a high frequency of the gene for NC-21-OHD would facilitate early diagnosis and treatment. Pubertal stage and bone age at the introduction of therapy dictate height prognosis. Initiation of therapy before puberty with careful follow-up and HC dose adjustment can assure the achievement of genetic adult height.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is limited evidence that initiation of GC treatment before puberty may improve adult height (320, 321).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [321]
Citations
Cites
Still being checked.
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Carmina, E., Dewailly, D., Escobar-Morreale, H. F., Kelestimur, F., Moran, C., Oberfield, S., Witchel, S. F., & Azziz, R. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx014 · Cited by 201
Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia
Moran, C., Azziz, R., Weintrob, N., Witchel, S. F., Rohmer, V., Dewailly, D., Marcondes, J. A. M., Pugeat, M., Speiser, P. W., Pignatelli, D., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0062 · Cited by 174
Self-citationNordenström, A., & Falhammar, H. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0712 · Cited by 158
Balsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030123 · Cited by 102
Pinto, G., Tardy, V., Trivin, C., Thalassinos, C., Lortat-Jacob, S., Nihoul-Fékété, C., Morel, Y., & Brauner, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021433 · Cited by 101
Novel strategies for hydrocortisone replacement
Debono, M., Price, J., & Ross, R. J. M. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.010 · Cited by 69
Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency
Weintrob, N., Brautbar, C., Pertzelan, A., Josefsberg, Z., Dickerman, Z., Kauschansky, A., Lilos, P., Peled, D., Phillip, M., & Israel, S. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430397 · Cited by 59
Self-citationLivadas, S., & Bothou, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00366 · Cited by 57
“In those patients in whom hydrocortisone treatment was initiated 1 year before the onset of puberty and who had a bone age below 9 years, final height remained within the genetic potential (47).”
BackgroundChallenges in treatment of patients with non-classic congenital adrenal hyperplasia
Adriaansen, B. P. H., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064024 · Cited by 51
Non-Classical Congenital Adrenal Hyperplasia in Childhood
Kurtoğlu, S., & Hatipoğlu, N. (2017) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.3378 · Cited by 49
Pregnancy in women with nonclassic congenital adrenal hyperplasia: time to conceive and outcome
Eyal, O., Ayalon‐Dangur, I., Segev‐Becker, A., Schachter‐Davidov, A., Israel, S., & Weintrob, N. (2017) · Clinical Endocrinology · doi:10.1111/cen.13429 · Cited by 47
Self-citationAdult height of subjects with nonclassical 21-hydroxylase deficiency
Eyal, O., Tenenbaum‐Rakover, Y., Shalitin, S., Israel, S., & Weintrob, N. (2013) · Acta Paediatrica · doi:10.1111/apa.12147 · Cited by 33
“While adult height (AH) has been studied extensively in classic CAH and shown to be compromised (6), data on AH in subjects with NC21OHD are sparse and inconsistent (3, 7).”
BackgroundSelf-citationNon-PCOS Hyperandrogenic Disorders in Adolescents
Esquivel-Zuniga, M. R., Kirschner, C. K., McCartney, C. R., & Solorzano, C. M. B. (2022) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1742259 · Cited by 31
Flash, S., Weil, C., Shalev, V., Oron, T., & Chodick, G. (2014) · Hormone Research in Paediatrics · doi:10.1159/000357444 · Cited by 27
Neeman, B., Bello, R., Lazar, L., Phillip, M., & de Vries, L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02605 · Cited by 26
Growth in congenital adrenal hyperplasia
Nguyen, A. T. T., Brown, J. J., & Warne, G. L. (2006) · The Indian Journal of Pediatrics · doi:10.1007/bf02758268 · Cited by 26
Kocova, M., Anastasovska, V., & Falhammar, H. (2020) · Endocrine · doi:10.1007/s12020-020-02323-3 · Cited by 24
Growth Trajectory and Adult Height in Children with Nonclassical Congenital Adrenal Hyperplasia
Wasniewska, M. G., Morabito, L. A., Baronio, F., Einaudi, S., Salerno, M., Bizzarri, C., Russo, G., Chiarito, M., Grandone, A., Guazzarotti, L., et al. (2020) · Hormone Research in Paediatrics · doi:10.1159/000509548 · Cited by 22
de Vries, L., Lebenthal, Y., Phillip, M., Shalitin, S., Tenenbaum, A., & Bello, R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00698 · Cited by 22
Kashimada, K., Makoto, O. N. O., ONISHI, T., KOYAMA, S., Toyoura, T., Imai, K., Saisho, S., & Mizutani, S. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-057 · Cited by 21
Pinkas, H., Fuchs, S., Aurbach-Klipper, Y., Zvulunov, A., Raanani, H., Sheffer-Mimouni, G., Fisch, B., & Weintrob, N. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.12.037 · Cited by 15
Self-citationBello, R., Lebenthal, Y., Lazar, L., Shalitin, S., Tenenbaum, A., Phillip, M., & de Vries, L. (2016) · Acta Paediatrica · doi:10.1111/apa.13630 · Cited by 13
21-Hydroxylase Genotyping in Australasian Patients with Congenital Adrenal Hyperplasia
Jeske, Y. W. A., McGown, I. N., Harris, M. A., Bowling, F. G., Choong, C. S., Cowley, D. M., & Cotterill, A. M. (2009) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2009.22.2.127 · Cited by 13
Kendırcı, H. N. P., Ünal, E., Dündar, İ., Buluş, A. D., Güneş, S. O., & Şıklar, Z. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-26-s · Cited by 11
Brener, A., Segev‐Becker, A., Weintrob, N., Stein, R., Interator, H., Schachter‐Davidov, A., Israeli, G., Elkon‐Tamir, E., Lebenthal, Y., Eyal, O., et al. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0617 · Cited by 11
Self-citationSinger, S., Pinhas‐Hamiel, O., & Botzer, E. (2001) · Clinical Pediatrics · doi:10.1177/000992280104001107 · Cited by 11
Medical treatment of classic and nonclassic congenital adrenal hyperplasia
Speiser, P. W. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8002-1_9 · Cited by 10
Segev‐Becker, A., Jacobson, R., Stein, R., Eyal, O., Oren, A., Schachter‐Davidov, A., Israeli, G., Lebenthal, Y., & Weintrob, N. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0509 · Cited by 10
Self-citationErdeve, Ş. S., Berberoğlu, M., Yurur-Kutlay, N., Şıklar, Z., Hacıhamdioğlu, B., Tükün, A., & Öçal, G. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.354 · Cited by 10
Ben‐Shachar, S., Ayalon, I., Reznik‐Wolf, H., Tenenbaum‐Rakover, Y., Zuckerman‐Levin, N., Cohen, O., Lifshitz, A., Fraenkel, M., Toledano, Y., Roash, V., et al. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1389901 · Cited by 9
Self-citationHiperplasia suprarrenal congénita no clásica o tardía
Alonso, M., & Ezquieta, B. (2012) · Cited by 8
Bello, R., Lazar, L., Phillip, M., & de Vries, L. (2023) · Hormone Research in Paediatrics · doi:10.1159/000529772 · Cited by 5
The way toward adulthood for females with nonclassic congenital adrenal hyperplasia
Ntali, G., Charisis, S., Kylafi, C. F., Vogiatzi, E., & Michala, L. (2021) · Endocrine · doi:10.1007/s12020-021-02715-z · Cited by 4
Hiperplasia suprarrenal congénita: diagnóstico, tratamiento y evolución a largo plazo
Labarta, J. I., Bello, E., Ferrández, A., & Mayayo, E. (2004) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(04)74628-8 · Cited by 4
de Vries, L., Baum, M., Horovitz, M., Phillip, M., Barash, G., Pinhas‐Hamiel, O., & Lazar, L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.08.005 · Cited by 3
Podgórski, R., Podgórska, D., & Sumińska, M. (2023) · Pediatria Polska · doi:10.5114/polp.2023.133534 · Cited by 2
Bello, E., Ruiz-Echarri, M., Rueda, C. F., Martul, P., Mayayo, E., & Longás, Á. F. (2016) · Cited by 2
Pignatelli, D., & Pereira, S. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82591-1_2 · Cited by 1
Herdean, A. M., Radulescu, A. M., & Ilie, I. R. P. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2580 · Cited by 1
Two Brothers with Non-Classical 21-Hydroxylase Deficiency: To Treat or Not to Treat?
Oberender, F., Rumsby, G., Perry, L. A., & Savage, M. O. (2004) · Hormone Research in Paediatrics · doi:10.1159/000081622 · Cited by 1
Letoutchi, L. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-6490
Nonclassic 21-Hydroxylase Deficiency and Short Stature in an Ethnically at-Risk Population
Agarwal, C., Hassoun, A. A., Aranoff, G. S., Pomeranz, C. B., & Oberfield, S. E. (2010) · The Endocrinologist · doi:10.1097/ten.0b013e3181e94b3c
Novel Therapies for Treating Short Stature with Congenital Adrenal Hyperplasia
Simpson, J. L., Hann, M., Kshetrapal, A., & New, M. I. (2011) · International Journal of Infertility & Fetal Medicine · doi:10.5005/jp-journals-10016-1017
Debates and Controversies in Genetic Steroid Disorders
Speiser, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00030-2
Зелінська, Н. Б. (2019) · The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy
Debates and controversies in genetic steroid disorders
Speiser, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00014-9
Hartrampf, S. (2009) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.9795
Metadata
- Authors
- Weintrob, N., Dickerman, Z., Sprecher, E., Galatzer, A., & Pertzelan, A.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Weintrob, Naomi
- Pertzelan, Atalia
- ORCID
- Weintrob, Naomi
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-02
- Volume
- 136
- Issue
- 2
- Pages
- 188-195
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2038884461
- Cited by
- 50
- References
- 0
- Citations by year
- 2024: 1 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 6 · 2018: 2 · 2017: 2 · 2016: 3 · 2014: 2 · 2013: 2 · 2012: 1
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, hydrocortisone therapy, puberty onset, adult height, peak height velocity, precocious puberty, hyperandrogenism, children, puberty suppression, growth hormone therapy, menarche, gonadarche
- MeSH terms
- Adrenal Hyperplasia, Congenital, Body Height, Child, Child, Preschool, Female, Glucocorticoids, Humans, Infant, Male, Puberty, Puberty, Precocious, Retrospective Studies, Testosterone, Time Factors, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.